Pharmacological treatment of osteoporosis for people over 70

Aging Clinical and Experimental Research

Volumn 19, Issue 3, 2007, Pages 246-254

  Álvarez, Ma Jesús Moro ^a   Díaz Curiel, Manuel ^b  

^a HOSPITAL CENTRAL DE LA CRUZ ROJA   (Spain)

^b Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

Aging; Anti osteoporotic treatment; Bone mineral density; Elderly; Fracture; Osteoporosis

Indexed keywords

25 HYDROXYVITAMIN D; ALENDRONIC ACID; CALCITONIN; CALCITRIOL; CALCIUM; COLECALCIFEROL; ERGOCALCIFEROL; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; RISEDRONIC ACID; STRONTIUM RANELATE; VITAMIN D;

AGING; ANALGESIC ACTIVITY; BONE DENSITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; FRAGILITY FRACTURE; GERIATRIC CARE; HIP FRACTURE; HUMAN; META ANALYSIS; MONOTHERAPY; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PHYSICAL PERFORMANCE; POST HOC ANALYSIS; POSTMENOPAUSE OSTEOPOROSIS; RECOMMENDED DRUG DOSE; REVIEW; RISK REDUCTION; TREATMENT DURATION; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION;

EID: 34447250091     PISSN: 15940667     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03324697     Document Type: Review

References (46)

1. Looker AC, Orwoll ES, Johnston CC Jr, et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res 1997; 12: 1769-71.
2. Melton LJ, Chrischilles EA, Cooper C, Lane AW, Riggs BL. Perspective. How many women have osteoporosis? J Bone Miner Res 1992; 7: 1005-10.
3. Díaz Curiel M, García JJ, Carrasco JL, et al. Prevalenda de osteoporosis determinada por densitometría en la población femenina española. Med Clin (Barc) 2001; 116: 86-8.
4. Kanis JA, Johnell O, Oden A, et al. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 2001; 12: 989-95.
5. Binkley N, Krueger D, Cowgill CS, et al. Assay variation confounds the diagnosis of hypovitaminosis D: a call for standardization. J Clin Endocrinol Metab 2004; 89: 3152-7.
6. Haller J. The vitamin status and its adequacy in the elderly: an international overview. Int J Vitam Nutr Res 1999; 69: 160.
7. Lim SK, et al. Congreso Internacional de la sociedad de densitometría clínica. New Orleans, 2005.
8. Dawson Hughes B, Dalla GE, Krall EA, et al. A controlled trial of the effect of calcium on bone density in postmenopausal women. N Engl J Med 1990; 323: 878-83.
9. Dawson Hughes B, Harris SS, Krall EA, Dalla GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997; 337: 670-6.
10. Chapuy MC, Arlot ME, Duboeuf F, et al.Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 1992; 327: 1637-42.
11. Grant AM, Avenell A, Campbell MK, et al; RECORD Trial Group. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium OR vitamin D, RECORD): a randomised placebo-controlled trial. Lancet 2005; 365: 1621-8.
12. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 2005; 293: 2257-64.
13. Pfeifer M, Begerow B, Minne HW, et al. Effects of a short term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. J Bone Miner Res 2000; 15: 1113-8.
14. Bischoff HA, Stahelin HB, Dick W et al. Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial J Bone Miner Res 2003; 18: 343-51.
15. Holick MF, Siris ES, Binkley N, et al. Prevalence of Vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab 2005; 90: 3215-24.
16. Emkey RD, Ettinger M. Improving compliance and persistence with bisphosphonate therapy for osteoporosis. Am J Med 2006; 119: S18-24.
17. Chesnut III CH, Silverman S, Adriano K, Genant H, and PROOF Study Group. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent of Osteoporotic Fracture Study. Am J Med 2000; 109: 267-76.
18. Cranney A, Tugwell P, Zytaruk N, et al. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocrine re views 2002; 23: 540-51.
19. Grupo de trabajo de la SEIOMM. Guia de práctica clínica sobre la osteoporosis postmenopaúsica de la SEIOMM. Available at: http://www.seiomm.org/documentos/osteoporosis_es_en.pdf
20. Cranney A, Waldegger L, Graham ID, Man-Son-hing M, Byszewsk A, Ooi DS. Systematic assessment of the quality of osteoporosis guidelines. BMC Musculoeskeletal Disorders 2002, 3: 20. Available at: http://www.biomedcentral.com/14712474/3/20
21. Brown JP, Josse RC, for the Scientific Advisory Council of Osteoporosis Society of Canada Jacques P. Clinical practice guide lines for the diagnosis and management of osteoporosis in Canada. Can Med Assoc J 2002; 167: 1-34. Available at: http://www.cmaj.ca/cgi/data/167/10_suppl/ s1/DC1/1
22. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in post-menopausal osteoporosis. The Alendronate Phase Osteoporosis Treatment Study Group. N Engl J Med 1995; 333: 1437-43.
23. Black DM, Cumming SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535-41.
24. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without, vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280: 2077-82.
25. Pols HA, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 1999; 9: 461-8.
26. Cranney A, Wells G, Willan A, et al. Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002; 23: 508-16.
27. Ensrud KE, Black DM, Palermo L, et al. Treatment with alendronate prevents fractures in women at highest risk. Arch Int Med 1997; 2617-24.
28. Hochberg MC, Thompson DE, Black D. The effect of alendronate on age-specific incidence of key osteoporotic fractures. Bone, 2001, 28, 5, Suppl, P576S. (Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society, June 2001, Madrid, Spain).
29. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999; 282: 1344-52.
30. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000; 11: 83-91.
31. McClung MR, Geusens P, Miller PD, et al. Effect of Risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001; 344: 333-40.
32. Cranney A, Tugwell P, Adachi J, et al. Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of post-menopausal osteoporosis. Endocr Rev 2002; 23: 517-23.
33. Boonen S, McClung MR, Eastell R, Fuleihan GE, Barton IP, Deimas P. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. J Am Geriatric Soc 2004; 52: 1832-9.
34. Heaney RP, Zizic TM, Fogelman I, et al. Risedronate reduces the risk of first vertebral fracture in osteoporotic women. Osteoporos Int 2002; 13: 501-5.
35. Sato Y, Kanoko T, Satoh K, Iwamoto J. The prevention of hip fracture with risedronate and ergocalciferol plus calcium supplementation in elderly women with Alzheimer disease: a randomized controlled trial. Arch Intern Med 2005; 165: 1737-42.
36. Sato Y, Kanoko T, Satoh K, Iwamoto J. Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Arch Intern Med 2005; 165: 1743-48.
37. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in post-menopuasal women with osteoporosis. N Engl J Med 2001; 344: 1434-41.
38. Lyndsay R, Scheele WH, Neer R, et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in post-menopausal women with osteoporosis. Arch Intern Med 2004; 18: 2024-30.
39. Capuzzo KA, Delafuente JC. Teriparatide for severe osteoporosis. Ann Pharmacother 2004; 38: 294-302.
40. Marcus R, Wang O, Satterwhite J, Mifiak B. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 2003; 18: 18-23.
41. Chesnut CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in post-menopausal osteoporosis. J Bone Miner Res 2004; 19: 1241-9.
42. Cooper C, Emkey RD, McDonald RH, et al. Efficacy and safety of oral weekly ibandronate in the treatment of posmenopausal osteoporosis. J Clin Endocrinol Metab 2003; 88: 4609-15.
43. Reginster JY, Deroisy R, Dougados M, Jupsin I, Colette J, Roux C. Prevention of early postmenopausal bone loss by strontium ranelate: the randomized two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial. Osteoporos Int 2002; 13: 925-31.
44. Meunier PJ, Roux C, Seeman E, et al: The effects of Strontium Ranelate on the risk of vertebral fracture in women with post-menopausal osteoporosis. N Engl J Med 2004, 350: 459-68.
45. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium Ranelate reduces the risk of nonvertebral fractures in post-menopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin End Metab 2005; 90: 2816-22.
46. Seeman E, Vellas B, Roux C, et al. First demosntration of the efficacy of an antiosteoporotic treatment in very elderly osteoporotic women. J Bone Miner Res 2004; 19 (Supl 1): 1219.